Latest research on Remicade

Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion

Latest findings

A recent study29 using 125 IBD patients' and controls' sera demonstrated that anti-Remicade antibodies in IBD patients recognize and functionally inhibit Remsima to a similar degree, suggesting similar immunogenicity profile. [source, 2016]
All 69 positive anti-Remicade sera were cross-reactive with Remsima. [source, 2016]
Antibody to infliximab titers against Remicade or Remsima were strongly correlated (r-values between 0.92 and 0.99, P<0.001). [source, 2016]
Anti-Remicade antibodies of IBD patients exerted similar functional inhibition on Remsima or Remicade TNF-α binding capacity. [source, 2016]
The RRR (remission induction by Remicade in RA) study was also undertaken to assess the possibility of discontinuation of infliximab DMARDs in established RA patients. [source, 2016]
Previously we have demonstrated the effects of a tumor necrosis factor-alpha (TNF-α) inhibitor infliximab's (Remicade, Merck&Co, Whitehouse Station, NJ, USA) effects on different experimental models of neuronal injury24,31,32). [source, 2015]
100 mg of Infliximab powder (Remicade) were dissolved in 1mL of sterilized distilled water, 24 mL of BSS were added and 4 mg/ mL of Eye Drops were produced. [source, 2015]
Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd. [source, 2015]
The annual sales of the top-selling antibody drugs, such as Humira, Remicade, Avastin, Rituxan and Herceptin, are over or close to $ 10 billion now while many potential blockbusters are being investigated in clinical trials [1, 2]. [source, 2015]
Five top-selling therapeutic antibodies which are also popular biosimilar candidates for many biotech companies, namely Herceptin (trastuzumab), Avastin (bevacizumab), Remicade (infliximab), Rituxan (rituximab) and Humira (adalimumab), were used as model molecules in this study. [source, 2015]